Abstract
Background: As a first step towards implementing routine screening of safety issues specifically related to children at the Uppsala Monitoring Centre, this study was performed to explore reporting patterns of adverse reactions in children.
Objective: The first aim of this study was to characterize and contrast child reports against adult reports in an overall drug and adverse reaction review. The second aim was to highlight increases in reporting of specific adverse reactions during recent years subdivided by age group.
Study Design: This was an exploratory study of internationally compiled individual case safety reports (ICSRs).
Setting: Reports were extracted from the WHO global ICSR database, VigiBase, up until 5 February 2010. The reports in VigiBase originate from 97 countries and the likelihood that a medicine caused the adverse effect may vary from case to case. Suspected duplicate and vaccine reports were excluded from the analysis, as were reports with age not specified. The Medical Dictionary for Regulatory Activities (MedDRA®) and the WHO Anatomical Therapeutic Chemical (ATC) classification were used to group adverse reactions and drugs.
Patients: In the general review, reports from 1968 to 5 February 2010 were divided into child (aged 0–17 years) and adult (≥18 years) age groups. To highlight increases in reporting rates of specific adverse reactions during recent years, reports from 2005 to February 2010 were compared with reports from 1995 to 1999. The ten adverse reactions with the greatest difference in the proportion of reports between the two time periods were reviewed. In the latter analysis, the reports were subdivided into age groups: neonates ≤27 days; infants 28 days–23 months; children 2–11 years; and adolescents 12–17 years.
Results: A total of 3 472 183 reports were included in the study, of which 7.7% (268 145) were reports for children (0–17 years). Fifty-three percent of the child reports were for males, whilst 39% of reports in the adult group were for males. The proportion of reports involving children among Asian reports was 14% and was 15% among reports from Africa and Latin America, including the Caribbean. Among reports from North America, Oceania and Europe, 7% of the reports involved children. For the ATC drug classification groups, the largest difference in percentage units between the child and adult groups was seen for the anti-infective (33 vs 15%), respiratory (11 vs 5%) and dermatological (12 vs 7%) drug groups. Skin reactions were most commonly reported for the children; these were recorded in 35% of all reports for children and 23% of all reports for adults. Medication error-related terms in the younger age groups were reported with an increased frequency during recent years. This was particularly noticeable for the infants aged 28 days–23 months, recorded with accidental overdose and drug toxicity. Reactions reported in suspected connection to medicines used for attention-deficit hyperactivity disorders (ADHD) completely dominated the 2-to 11-year age group and were also common for the adolescents. This study presents variations in the reporting pattern in different age groups in VigiBase which, in some cases, could be due to susceptibilities to specific drug-related problems in certain age groups. Other likely explanations might be common drug usage and childhood diseases in these age groups.
Conclusions: Reports in VigiBase received internationally for more than 40 years reflect real concerns for children taking medicines. The study highlights adverse reactions with an increased reporting during recent years, particularly those connected to the introduction of ADHD medicines in the child population. To enhance patient safety, medication errors indicating administration and dosing difficulties of drugs, especially in the younger age groups, require further attention.
Similar content being viewed by others
References
World Health Organization. Promoting safety of medicines for children. Geneva: World Health Organization, 2007
World Health Organization. Make medicines child size [online]. Available from URL: http://www.who.int/childmedicines/en/ [Accessed 2010 Apr 2]
Steinbrook R. Testing medications in children. N Engl J Med 2002 Oct 31; 347(18): 1462–70
US Food and Drug Administration Center for Drug Evaluation and Research. Pediatric drug development [online]. Available from URL: http://www.fda.gov/cder/pediatric/ [Accessed 2010 Apr 2]
European Medicines Agency. Paediatric medicine development [online]. Available from URL: http://www.emea.europa.eu/htms/human/paediatrics/introduction.htm [Accessed 2010 Apr 2]
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005 Sep; 164(9): 552–8
Turner S, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998 Jan 31; 316(7128): 343–5
Blumer JL. Off-label uses of drugs in children. Pediatrics 1999 Sep; 104 (3 Pt 2): 598–602
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29(5): 385–96
Finney DJ. An international drug safety program. J New Drugs 1963 Sep–Oct; 15: 262–5
Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005 Feb 5–11; 365(9458): 482–7
Meyboom RH. Adverse reaction to drugs in children, experiences with “spontaneous monitoring” in The Netherlands. Bratisl Lek Listy 1991 Nov; 92(11): 554–9
Morales-Olivas FJ, Martinez-Mir I, Ferrer JM, et al. Adverse drug reactions in children reported by means of the yellow card in Spain. J Clin Epidemiol 2000 Oct; 53(10): 1076–80
Kimland E, Rane A, Ufer M, et al. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 2005 Jul; 14(7): 493–9
Johann-Liang R, Wyeth J, Chen M, et al. Pediatric drug surveillance and the Food and Drug Administration’s adverse event reporting system: an overview of reports, 2003–2007. Pharmacoepidemiol Drug Saf 2009 Jan; 18(1): 24–7
Carleton BC, Smith MA, Gelin MN, et al. Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol 2007 Winter; 14(1): e45–57
Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002 Dec; 87(6): 462–6
Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf 2010 Apr 1; 33(4): 327–39
Moore TJ, Weiss SR, Kaplan S, et al. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002 Nov; 110(5): e53
Verhamme K, Bonifazi F, Ceci A, et al. Adverse drug reactions reporting in children. Pharmaceut Policy Law 2009; 11: 89–99
Lindquist M. Vigibase, the WHO Global ICSR Database system: basic facts. Drug Inf J 2008; 42(5): 409–19
MedDRA —the Medical Dictionary for Regulatory Activities: the MSSO-Maintenance and Support Services Organization [online]. Available from URL: http://www.meddramsso.com/ [Accessed 2010 Mar 29]
Norén GN, Orre R, Bate A, et al. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 2007; 14: 305–28
Letourneau M, Wells G, Walop W, et al. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database. Vaccine 2008 Feb 26; 26(9): 1185–94
WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2008. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2009
European Medicines Agency. ICH topic E 11. Clinical investigation of medicinal products in the paediatric population. 2001 Jan. CPMP/ICH/2711/99 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/271199en.pdf [Accessed 2009 Jun 10]
Fluhr JW, Pfisterer S, Gloor M. Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol 2000 Nov–Dec; 17(6): 436–9
Population reference bureau. World population data sheet 2009 [online]. Available from URL: http://www.prb.org/pdf09/09wpds_eng.pdf [Accessed 2010 Mar 1]
Fridén S, Star K, Norén GN. Gender distribution in international adverse drug reaction surveillance. Drug Saf 2009; 32(10): 929
Kiuru A, Lindquist M. Why do boys stop crying? Drug Saf 2005; 28(10): 925–69
Dey AN, Schiller JS, Tai DA. Summary health statistics for U.S. children: national health interview survey, 2002. National Center for Health Statistics. Vital Health Stat 2004; 10 (221) [online]. Available from URL: http://www.cdc.gov/nchs/data/series/sr_10/sr10_221.pdf [Accessed 2010 Apr 6]
Sturkenboom MC, Verhamme KM, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ 2008; 337(7682): 1338–41
Vernacchio L, Kelly JP, Kaufman DW, et al. Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics 2009; 124(2): 446–54
Abi Khaled L, Ahmad F, Brogan T, et al. Prescription medicine use by one million Canadian children. Paediatr Child Health 2003; 8 Suppl. A: 6–56A
Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol 2009 Jun; 67(6): 687–90
Alj L, Touzani MDW, Benkirane R, et al. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med 2007; 19(4): 187–94
Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999
Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004 Jun; 24(6): 743–9
Electronic Medicines Compendium. Atomoxetine [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/14482/SPC/Strattera++10mg%2c+18mg%2c+25mg%2c+40mg%2c+60mg+or+80mg+hard+capsules./#OVERDOSE [Accessed 2010 May 15]
US Food and Drug Administration. Historical information on antidepressant use in children, adolescents, and adults [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096293.htm [Accessed 2010 May 13]
European Medicines Agency. CHMP meeting on paroxetine and other SSRIs [press release]. 2004 Dec 9 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pr/19257004en.pdf
Meyboom RH, Lindquist M, Flygare AK, et al. The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Saf 2000 Aug; 23(2): 95–9
Acknowledgements
The authors are indebted to the National Centres that contributed data. The opinions and conclusions in this study are not necessarily those of the various centres or of the WHO.
No sources of funding were used to prepare this manuscript or conduct this study. The authors have no conflicts of interest to declare that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Star, K., Norén, G.N., Nordin, K. et al. Suspected Adverse Drug Reactions Reported For Children Worldwide. Drug-Safety 34, 415–428 (2011). https://doi.org/10.2165/11587540-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11587540-000000000-00000